Brought to you by:
FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of Magnitude drug-eluting bioresorbable scaffold
R3 Vascular today announced that the Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of the next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee (BTK) peripheral arterial disease (PAD). “We are…
Endoscopic vein harvest under the microscope
Conflicting results open fresh debate around effect of vein harvesting technique on long-term patency of lower extremity bypass grafts. Two separate analyses that looked at the impact made by the method used to harvest great saphenous vein (GSV) on the…
Study details aspects of early care improvements after publication of SVS appropriate use criteria for claudication
An observational study of intermittent claudication (IC) practice patterns before and after publication of the Society for Vascular Surgery (SVS) appropriate use criteria (AUC) for IC management points to a series of areas where care has improved, alongside aspects still…
Novel RCT framework set to improve design and reporting of endovascular infrainguinal lower-limb interventions for PAD
Pilot testing has shown that a new framework—dubbed Endo-STAR—can be used to describe and standardise endovascular interventions for peripheral arterial disease (PAD) within a randomised controlled trial (RCT) protocol and monitor adherence to the protocol over the course of a…
The Shockwave E8 experience: Featuring the new Shockwave peripheral IVL workhorse
This advertorial is sponsored by Shockwave Medical. Paul J. Foley III, MD, a vascular surgeon and director of the non-invasive vascular lab at Doylestown Hospital in Doylestown, Pennsylvania, and adjunct associate professor of surgery at the University of Pennsylvania in…
Pulse IVL system US pivotal trial enrolls first patient
Amplitude Vascular Systems (AVS) recently announced that it has enrolled the first patient in its U.S. pivotal trial for pulsatile intravascular lithotripsy (IVL) therapy. A press release notes that the POWER PAD II clinical study will evaluate the safety and…
Laser atherectomy redefined: Breakthrough 355nm technology opens next frontier in treatment
In this supplement, sponsored by AngioDynamics:
Smoking: BEST-CLI trial points to protective effect against MALE in those undergoing open bypass over endovascular intervention
An analysis of the BEST-CLI randomized controlled trial (RCT) found that smokers with chronic limb-threatening ischemia (CLTI) should be preferentially treated with open bypass over endovascular intervention. Researchers from the University of California San Diego (UCSD) looked at BEST-CLI patients…
The CLTI conundrum: My spirited journey through the CLTI saga
Welcome to the CLTI Chronicles, a saga of mystery, medicine and misadventures in limb salvage unfolding weekly in my office, where the drama of threatened limbs rivals any Latin telenovela. My clinic has become a crossroads for the second opinion…
Eastern Vascular Society presidency transfers from Ozsvath to Lal
Brajesh K. Lal, MD, assumed the Eastern Vascular Society (EVS) presidency during the 2024 EVS annual meeting in Charleston, South Carolina (Sept. 19–22). The professor of surgery at the University of Maryland School of Medicine in Baltimore took over from…